Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2025-12-25 @ 4:12 AM
NCT ID:
NCT06817720
Brief Summary:
To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
Detailed Description:
Primary Objectives
* To assess the rate of MMR by 12 months. Secondary Objectives
* To assess the rate of CCyR by 12 months.
* To estimate the proportion of participants with 4.5-log reduction of BCR::ABL1 transcripts (MR4.5) at 6, 12, 18, 24, and 36 months of therapy.
* To estimate the rate of sustained deep molecular response.
* To estimate event-free survival and overall survival.
* To assess the toxicity of olverembatinib monotherapy.
* To assess health-related quality of life (HRQOL) of the participants.
Study:
NCT06817720
Study Brief:
Protocol Section:
NCT06817720